|
2024
|
Invention
|
Oncolytic adenovirus, immune checkpoint inhibitor and chemoterapeutic agent combination therapy o... |
|
|
Invention
|
Novel dosage regimen for an oncolytic adenoviral vector. According to an example aspect of the pr... |
|
2023
|
Invention
|
Monoclonal pd-l1 antibodies. According to an example aspect of the present invention, there is pr... |
|
2022
|
Invention
|
An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide.
The present invention pro... |
|
|
Invention
|
An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide. The present invention prov... |
|
|
Invention
|
Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto.
T... |
|
2020
|
Invention
|
An oncolytic virus vector coding for variant interleukin-2 (vil-2) polypeptide.
The present inve... |
|
|
Invention
|
An oncolytic virus vector coding for variant interleukin-2 (vil-2) polypeptide. The present inven... |
|
|
Invention
|
Enhanced adoptive cell therapy. There is disclosed oncolytic adenoviral vectors alone or together... |
|
|
Invention
|
Oncolytic adenovirus and checkpoint inhibitor combination therapy.
The present invention relates... |
|
|
Invention
|
Oncolytic adenovirus and checkpoint inhibitor combination therapy. The present invention relates ... |
|
2017
|
Invention
|
Interleukin 8 (il-8) as a prognostic and predictive biomarker and compositions and vectors for us... |
|
|
G/S
|
Scientific research and development for medical purposes; medical and biotechnological research; ... |
|
|
G/S
|
Scientific research and development for medical purposes;
medical and biotechnological research;... |
|
2016
|
Invention
|
Enhanced adoptive cell therapy. The present invention relates to the fields of life sciences and ... |
|
|
Invention
|
Oncolytic adenoviruses coding for bi-specific antibodies. The present invention relates to the fi... |
|
|
Invention
|
Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto. Th... |
